NTL Healthcare, a specialized company in

women's cancer, recently announced that

it participated in the world's largest medical

device exhibition, 'MEDICA 2023,' held in

Dusseldorf, Germany, and drew attention

from overseas buyers by showcasing its

artificial intelligence (AI) cervical cancer

screening system called CerviCARE® AI.

 

 

MEDICA is the world's largest medical device

exhibition, with around 500 companies from

around the world participating this year, and

83,000 medical professionals attending.

About 300 domestic companies participated,

and it was successfully held with great interest

from domestic and international companies

and experts. NTL Healthcare is a women's

cancer specialized company that has

introduced the analogue cervical cancer

screening system 'Cervicography' for the

first time in Korea and has developed

CerviCARE AI based on the accumulated

big data for cervical cancer screening.

 

 

NTL Healthcare was selected as a domestic

excellent company for overseas exhibition

support by K-Medi Hub (Daegu-Gyeongbuk

Medical Innovation Foundation) and operated

a booth at 'MEDICA 2023.' In particular,

NTL Healthcare's representative AI cervical

cancer screening system, CerviCARE AI, and

device such as Dr. Cervicam C20 were exhibited.

CerviCARE AI can classify cervical cancer test

results as normal or abnormal within

seconds based on the accumulated cervical

images big data by NTL. It can differentiate

and indicate cervical morphological

abnormalities supporting clinical

decisions in determining further treatment

directions. It is an innovative screening system

with the advantage of supporting the

additional medical treatment directions.

 

 

Through this exhibition, NTL Healthcare explored

new collaboration opportunities for business

expansion through meetings with more than

130 companies from 30 countries, including

major European countries such as Germany,

Italy, Poland, and France, as well as Brazil,

Kazakhstan, and Saudi Arabia. NTL, which has

already successfully made its overseas debut,

aims to further expand its market by

aggressively pursuing overseas expansion

through 'MEDICA 2023.'

 

 

Taehee Kim, CEO of NTL Healthcare, explained,

"Participating in 'MEDICA 2023' was an

opportunity to continuously communicate with

existing overseas buyers spread across 60

countries and also secure potential customers.

We are focused on widely showcasing the

excellence of CerviCARE AI with the goal of

exploring the overseas market."